| Similar Articles |
|---|
 |
The Motley Fool
January 25, 2007
Brian Gorman |
Covance Stays Solid Despite a run-up in the stock, Covance may be in for yet another solid year.   |
The Motley Fool
April 25, 2005
Brian Gorman |
Leaning on a Stronger Covance The drug development services company is helping big pharmaceutical firms. While the company's valuation of 24 times 2005 earnings is a bit a rich, Covance should be on investors' radar. |
The Motley Fool
April 28, 2006
Brian Gorman |
Speed Bumps at Covance Although some problems have cropped up, this drug-research services company is still a solid performer overall. Investors, take note. |
The Motley Fool
January 27, 2006
Brian Gorman |
Covance Keeps Humming The provider of drug research services will likely continue to deliver, even if one measure shows signs of tapering off. As a long-term investment, Covance looks like a good bet. |
The Motley Fool
July 22, 2011 |
Covance Earnings Preview Drug development company Covance beat estimates by $0.02 last quarter, and investors are hoping it can beat them again. |
The Motley Fool
October 21, 2005
Brian Gorman |
Covance Keeps Delivering Investors seemed to fret over the drug-development services company's full-year earnings forecast, but the facts suggest that Covance remains a solid long-term bet. |
The Motley Fool
June 15, 2006
Brian Gorman |
Covance Gets Strategic The drug research service company's latest deal could help it cement its leadership in the industry. Investors, take note. |
The Motley Fool
July 30, 2009
Robert Steyer |
Covance Advances Covance latest results produce more optimism than did some of its contract research peers. |
The Motley Fool
January 27, 2005
Brian Gorman |
Covance's Higher Performance The provider of drug development services' productivity gains and bundled service strategy are driving results. |
The Motley Fool
October 1, 2008
Brian Orelli |
WuXi and Covance Call It Quits WuXi PharmaTech and Covance broke up yesterday - just three months after announcing they'd form an alliance to perform pre-clinical research for drug developers looking for research and development on the cheap. |
The Motley Fool
August 3, 2004
Brian Gorman |
PAREXEL Gets Leaner The research services provider continues to improve operating performance, but that might not affect its stock price. |
Pharmaceutical Executive
December 1, 2012
Torrey et al. |
Transforming Drug Development: A Case Study Eli Lilly's pioneering pact with leading CRO Covance made big news when it happened. Four years later, both parties can point to metrics that suggest the benefit is mutual. |
The Motley Fool
May 18, 2010
Brian Orelli |
Pfizer Double-Dips Is this the best way to go after multiple indications? The drugs are already approved or have been in the clinic for other indications; thus the double-dipping. |
The Motley Fool
October 23, 2009
Robert Steyer |
Taking the Drug Industry's Temperature Covance and Icon hint at broader pharmaceutical R&D trends. |
The Motley Fool
June 7, 2005
Brian Gorman |
Covance Under Fire The contract research company could suffer at the hands of the animal-rights group PETA. The value of a company's public image is hard to quantify. For investors, this is definitely a case worth watching. |
The Motley Fool
November 7, 2006
Brian Gorman |
Charles River Inches Forward The drug research services company is not out of the woods yet, but some positive signs are emerging. Investors, take note. |
The Motley Fool
April 27, 2010
Brian Orelli |
Big Acquisition, Double-Digit Decline. Charles River Labs buys into China big time. But investors would rather have seen it stay home. |
The Motley Fool
June 25, 2008
Brian Orelli |
WuXi's Shortsighted Deal WuXi partners with Covance, but is it really a good long-term play? |
The Motley Fool
January 10, 2006
Stephen D. Simpson |
Can ICON Be a Paragon of Growth? The clinical research organization specialist and stock have recovered from some troubles, but do current valuations leave much on the table? |
The Motley Fool
February 1, 2008
Rich Smith |
Boeing Keeps Climbing The plane maker once again obliterates estimates. |
Chemistry World
November 12, 2014
Phillip Broadwith |
Labcorp to buy Covance and enter contract research Medical diagnostics specialist Labcorp has agreed to buy contract research organization Covance for around $6 billion. |
The Motley Fool
July 22, 2004
Brian Gorman |
Stability for Covance? After a solid quarter, the drug development service company may have found a way to keep revenue consistent. |
The Motley Fool
January 22, 2008
Rich Smith |
Foolish Forecast: Generally Less Dynamic? In advance of earnings, analysts expect defense contractor General Dynamics to show a quarterly sales increase of 16% and a big rise in profits too. |
The Motley Fool
January 29, 2008
Rich Smith |
Foolish Forecast: Boeing's da Bomb In advance of earnings, analysts and investors wonder if Boeing will make it twenty straight quarters of beating estimates. |
The Motley Fool
July 25, 2008
Rich Smith |
General Dynamics: Still Too Expensive? Down 4% over the past three months, General D's stock is headed in the right direction from a prospective buyer's point of view. But is it still too expensive? |
The Motley Fool
January 13, 2011
Brian Orelli |
This Trendy Pharma Is Making a Stylish Move Merck signs up a CRO to help with biosimilars. |
The Motley Fool
October 25, 2005
W.D. Crotty |
Lockheed's Peculiar Spin The defense contractor announces positive third quarter results but downplays a few troubling numbers. Skepticism aside, the company's stock seems reasonably priced when compared with its peers. |
The Motley Fool
January 27, 2011
Seth Jayson |
Here's How Pharmaceutical Product Development May Be Failing You Here's the current margin snapshot for Pharmaceutical Product Development and some of its sector and industry peers and direct competitors. |
The Motley Fool
August 9, 2006
Brian Gorman |
Charles River's Uptick The drug research services company looks better than it did last quarter, but it still has its issues. Investors, take note. |
The Motley Fool
May 11, 2006
Stephen D. Simpson |
Can Perini Add More Stories to Its Stock Price? A robust backlog and stock price suggest the story is out on this engineering and construction firm. |
